Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Penpulimab + SBRT in Metastatic NSCLC
NCT05485350Phase 2Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2022
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
01
Overview
A Phase 2 trial of anlotinib, penpulimab in non-small cell lung cancer (NSCLC), sponsored by Peking University Third Hospital. Status: unknown.
02
Drugs
anlotinibpenpulimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05485350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485350.